A 2024 study looking at SCLC tumor evolution throughout treatment found that patients with mutations in the lysine acetyltransferase genes CREBBP and EP300 have an elevated risk of disease recurrence, implicating these genes in therapeutic resistance [13]. The gene discussed is CREBBP; the disease is small cell lung carcinoma.